Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Broker Notes
Expert says buy these ASX expensive defensives as market momentum is peaking
Broker Notes
Top brokers name 3 ASX shares to sell today
Blue Chip Shares
2 ASX 200 blue chip shares rated as buys
How to invest
How shares with massive PE ratios can be cheap
Healthcare Shares
2 excellent healthcare ASX shares with strong long term growth potential
Share Market News
Top ASX shares to buy in May 2021
Share Market News
Top broker picks ASX shares next in line for a profit upgrade
⏸️ ASX Shares
2 compelling ASX 200 blue chip shares to buy in April
Growth Shares
2 of the best ASX shares to buy now
Share Market News
Aussie dollar tipped to weaken and this ASX share stands to gain the most
Growth Shares
3 outstanding ASX shares to buy and hold
Growth Shares
Where to reinvest your Fortescue (ASX:FMG) dividends
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
